REDEFINE 3: CagriSema Phase 3 trial (NCT05669755)
The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Active, not recruiting
- Enrolment
- 7,101
- actual
- Start
- 1 Mar 2023 (actual)
- Primary completion
- 1 Sep 2027 (estimated)
- Sponsor
- Novo Nordisk A/S
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| CagriSema | Experimental | Drug: Cagrilintide; Drug: Semaglutide | Participants will receive cagrilintide and semaglutide subcutaneously (s.c.) once-weekly after a dose escalation period of 16 weeks during the maintenance period of 219 weeks. |
| Placebo | Placebo comparator | Drug: Placebo | Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide s.c. once weekly for 235 weeks. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke | From baseline (week 0) to end of study (up to 242 weeks or more) |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Time to first occurrence of a composite endpoint: Onset of persistent ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy, Kidney death and CV death | From baseline (week 0) to end of study (up to 242 weeks or more) |
| Time to first occurrence of composite endpoint consisting of: Onset of persistent macro albuminuria, ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy and kidney death | From baseline (week 0) to end of study (up to 242 weeks or more) |
| Time to first occurrence of an expanded 5-point MACE composite endpoint consisting of: CV death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation and unstable angina requiring hospitalisation | From baseline (week 0) to end of study (up to 242 weeks or more) |
| Time to first occurrence of a composite endpoint consisting of: all-cause death, non-fatal myocardial infarction and non-fatal stroke | From baseline (week 0) to end of study (up to 242 weeks or more) |
| Time to first occurrence of myocardial infarction (fatal and non-fatal) | From baseline (week 0) to end of study (up to 242 weeks or more) |
| Time to first occurrence of stroke (fatal and non-fatal) | From baseline (week 0) to end of study (up to 242 weeks or more) |
| Change in eGFRcr (CKD-EPI) | From baseline (week 0) to 120 weeks |
| Ratio to baseline in Urine albumin-to-creatinine ratio (UACR) | From baseline (week 0) to 120 weeks |
| Relative change in body weight | From baseline (week 0) to 120 weeks |
| Change in waist circumference | From baseline (week 0) to 120 weeks |
| Change in waist-to-height ratio | From baseline (week 0) to 120 weeks |
| Change in systolic blood pressure (SBP) | From baseline (week 0) to 120 weeks |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 55 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular DiseaseClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.